ProGen Search
Intelligence Vault
CDMO

Cell and Gene Therapy Manufacturing and Logistics Assessment: Preview Report

A free preview of how ProGen's cell and gene therapy manufacturing and logistics assessment is built. Eight dated registers follow the chain from plasmid and viral vector to cell processing, release, the cold chain and the treatment site, and feed an eight-part diligence framework. Results are reserved for buyers.

PDF9 pagesPublished November 2026Free

Built to order · Research cut-off: 18 November 2026

What this report answers

  • Which contract manufacturers make viral vector and process cells for third parties today?
  • Which providers have closed sites, changed owner or exited since 2023?
  • What do FDA approvals and regulatory records show for a manufacturing decision?
  • What does the vein-to-vein register hold for each patient-specific product?
  • What does a buyer of the full assessment receive?

80 contract manufacturers

Screened worldwide for third-party GMP viral vector or cell therapy manufacturing; 69 classified as operating in 2026.

44 consolidation events

Recorded closures, sales, layoffs, exits, pauses and insolvencies in CGT manufacturing, January 2023 to November 2026.

What the analysis establishes

Eighty contract manufacturers

80 organizations screened worldwide for third-party GMP viral vector or cell therapy manufacturing, 69 classified as operating in 2026, each with its owner, modalities, sites where confirmed, stated scale and 2026 status.

Consolidation since 2023

44 recorded closures, sales, mergers, layoffs, program exits, pauses and insolvencies from January 2023 to November 2026, one row per real-world event. The preview shows one sample row field by field.

Release, approvals and setbacks

The 55 entries on the FDA's list of approved cellular and gene therapy products as of 30 October 2026, and 23 regulatory and manufacturing records since 2023: complete response letters, clinical holds, review extensions, inspection findings and related context.

Vein to vein, demand and leadership

Treatment sites, turnaround and manufacturing success for 20 patient-specific products, where sponsors disclose them; in vivo CAR-T deals and allogeneic and autoimmune milestones; and 33 leadership records since September 2024.

Built to your decision

Each assessment is scoped to a program, a provider shortlist or an investment, and quoted on request.

About this intelligence

More than 300 cited public sources and more than 340 dated facts behind eight registers. Sources include the FDA, ClinicalTrials.gov, company filings, press releases and disclosures. Other sources are proprietary ProGen intelligence sources. Facts are linked to their sources; interpretation is labeled "ProGen reading". Evidence is current to 18 November 2026.

Developers choosing or changing a manufacturing partner. Investors diligencing a CGT company or a CGT CDMO. Partnering and corporate development teams. Operations leaders planning a move to commercial supply.

Contents

  • Why a CGT manufacturing and logistics assessment
  • The questions it answers
  • How the assessment is built
  • The eight registers
  • Capacity: the contract manufacturer universe
  • Consolidation since 2023
  • Release: approvals and setbacks
  • Vein to vein
  • Demand: what programs will need next
  • Leadership: who runs the sites
  • The diligence framework
  • The evidence base
  • What a buyer receives

Registers in the assessment

Contract manufacturer universe, Consolidation events, FDA approvals, Regulatory and manufacturing records, Vein-to-vein by product, Demand-shift deals and milestones, Leadership records, Clinical pipeline

Free report

The full 9-page briefing is free. Tell us where to send it and it downloads immediately.

Related analysis